GeneDx Holdings Corp. (NASDAQ:WGS) — Market Cap & Net Worth
Market Cap & Net Worth: GeneDx Holdings Corp. (WGS)
GeneDx Holdings Corp. (NASDAQ:WGS) has a market capitalization of $1.89 Billion ($1.89 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6480 globally and #1911 in its home market, demonstrating a -1.30% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GeneDx Holdings Corp.'s stock price $65.38 by its total outstanding shares 28904590 (28.90 Million). Analyse GeneDx Holdings Corp. cash conversion from operations to see how efficiently the company converts income to cash.
GeneDx Holdings Corp. Market Cap History: 2020 to 2026
GeneDx Holdings Corp.'s market capitalization history from 2020 to 2026. Data shows change from $10.53 Billion to $1.89 Billion (-25.26% CAGR).
Index Memberships
GeneDx Holdings Corp. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.08% | #155 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #694 of 3165 |
Weight: GeneDx Holdings Corp.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
GeneDx Holdings Corp. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GeneDx Holdings Corp.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.29x
GeneDx Holdings Corp.'s market cap is 7.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $10.53 Billion | $179.32 Million | -$241.34 Million | 58.72x | N/A |
| 2021 | $4.25 Billion | $212.19 Million | -$245.39 Million | 20.05x | N/A |
| 2022 | $251.82 Million | $234.69 Million | -$548.98 Million | 1.07x | N/A |
| 2023 | $79.49 Million | $202.57 Million | -$175.77 Million | 0.39x | N/A |
| 2024 | $2.23 Billion | $305.45 Million | -$52.29 Million | 7.29x | N/A |
Competitor Companies of WGS by Market Capitalization
Companies near GeneDx Holdings Corp. in the global market cap rankings as of May 2, 2026.
Key companies related to GeneDx Holdings Corp. by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #126 globally with a market cap of $176.29 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $123.72 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #578 globally with a market cap of $45.31 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #643 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.29 Billion | $469.21 |
| #189 | Danaher Corporation | NYSE:DHR | $123.72 Billion | $175.15 |
| #578 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.31 Billion | $567.46 |
| #643 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
GeneDx Holdings Corp. Historical Marketcap From 2020 to 2026
Between 2020 and today, GeneDx Holdings Corp.'s market cap moved from $10.53 Billion to $ 1.89 Billion, with a yearly change of -25.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.89 Billion | -49.73% |
| 2025 | $3.76 Billion | +68.73% |
| 2024 | $2.23 Billion | +2702.91% |
| 2023 | $79.49 Million | -68.43% |
| 2022 | $251.82 Million | -94.08% |
| 2021 | $4.25 Billion | -59.60% |
| 2020 | $10.53 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of GeneDx Holdings Corp. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.89 Billion USD |
| MoneyControl | $1.89 Billion USD |
| MarketWatch | $1.89 Billion USD |
| marketcap.company | $1.89 Billion USD |
| Reuters | $1.89 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The compan… Read more